United States set
Menu Shopping cart $0 Search
Distributed product

Serum CrossLaps® (CTX-I) ELISA

  • Regulatory status:FDA
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:C-terminal telopeptide I, carboxy-terminal collagen I crosslinks
  • Species:Human
Cat. No. Size Price

AC-02F1 96 wells $1068,14
PubMed Product Details
Technical Data


Sandwich ELISA, HRP-labelled antibody


The Serum CrossLaps® (CTX-I) ELISA is an enzyme immunological test for the quantification of degradation products of C-terminal telopeptides of Type I collagen in human serum and plasma.
The Serum CrossLaps® (CTX-I) ELISA assay is intended for in-vitro diagnostic use as an indication of human bone resorption and may be used as an aid in:

A) Monitoring bone resorption changes of:
a) Anti-resorptive therapies in postmenopausal women:

  • Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
  • Bisphosphonate therapies

b) Anti-resorptive therapies in individuals diagnosed with osteopaenia:

  • Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
  • Bisphosphonate therapies

B) Predicting skeletal response (Bone Mineral Density) in postmenopausal women undergoing anti-resorptive therapies:
a) Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
b) Bisphosphonate therapies

Scientific Description

Type I collagen accounts for more than 90% of the organic matrix of bone and is synthesised primarily in bone. During renewal of the skeleton, Type I collagen is degraded and small peptide fragments are excreted into the bloodstream. Serum levels of these degradation products, such as CTX-I, are highly correlated with the bone turnover rate and allow an assessment of the rate of bone resorption.
The Serum CrossLaps® (CTX-I) ELISA is based on two highly specific monoclonal antibodies against the amino acid sequence of EKAHD-ß-GGR, where the aspartic acid residue (D) is ß-isomerised. In order to obtain a specific signal in the Serum CrossLaps® (CTX-I) ELISA, two chains of EKAHD-ß-GGR must be cross-linked.
As of late 2010, IOF and IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) recommend the serum CTX-I as a bone resorption marker for use in observational and intervention studies, in order to compare the performance of alternatives and to widen international experience of the application of bone markers to clinical medicine.


Serum, Plasma

Sample Requirements

50 μl/well


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

0-3.380 ng/ml

Limit of Detection

0.020 ng/mL CrossLaps



  • Management of Postmenopausal Osteoporosis
  • Prediction of long-term skeletal response to anti-resorptive therapies, e.g. HRT, bisphosphonates
  • Increase in patient motivation and compliance
  • Assessment of Bone Resorption in Patients
  • With metabolic bone disease, e.g. hyperparathyroidism, Paget´s disease, osteodystrophy
  • Receiving prolonged glucocorticoid therapy
  • A reference marker for osteoporosis management as indicated by IOF, IFCC and NBHA
  • Easy to perform – one step incubation
  • Excellent correlation with automated methods

Research topic

Bone and cartilage metabolism, Extracellular matrix

Related Products Docs

Safety Information (FDA)


Find documents for the lot